Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Corbus Pharmaceuticals Holdings (CRBP) Change in Receivables (2017 - 2018)

Corbus Pharmaceuticals Holdings has reported Change in Receivables over the past 2 years, most recently at -$6.2 million for Q2 2018.

For Q2 2018, Change in Receivables changed N/A year-over-year to -$6.2 million; the TTM value through Sep 2019 reached -$6.2 million, up 51.92%, while the annual FY2019 figure was -$5.0 million, 60.0% up from the prior year.
Change in Receivables for Q2 2018 was -$6.2 million at Corbus Pharmaceuticals Holdings, roughly flat from -$6.2 million in the prior quarter.
Over five years, Change in Receivables peaked at $500000.0 in Q3 2017 and troughed at -$6.2 million in Q1 2018.